## KEY HIGHLIGHTS

1. RESULTS OVERVIEW:

- Kajaria Ceramics Ltd Q4FY23 consolidated revenues came in at ₹ 1203 Cr , up by $9.17 \%$ YoY and up by $10.26 \%$ QoQ.
- Op Profit for Q4FY23 stood at ₹176 Cr, up by $6.02 \%$ YoY and $32.33 \%$ QoQ.
- Op margins for Q4FY23 came at $15 \%$, flat YoY and +300bps QoQ.
- Net profit for Q4FY23 stood at ₹111Cr up by $14.43 \%$ YoY and up by $50 \%$ QoQ.


## 2. MANAGEMENT COMMENTARY:

- FY23 has been a challenging year due to high inflation and gas supply disturbances.
- Currently domestic tile market stands at Rs. 42000 crores for domestic and Rs. 17500 crores for exports.
- Management has sold 101 million square meters of tiles in FY23 and aims to double it in next 5-6 years.
- Management has guided to do $13 \%-15 \%$ volume growth, revenue growth of 14\%-16\% along with 14\%-16\% EBITDA margins.


## 3. CONCALL SUMMARY

- Management has guided for Rs. 250 crores of capex every year for additional capacity expansion.
- The management anticipates the export market to reach more than ₹ 20,000 crore by end of this year.
- No price hikes are on the radar for FY24. Last year company did a price hike in the range of $4 \%-5 \%$.
- In sanitary ware and faucet ware, the management guided to achieve ₹ 440 - ₹ 450 crore in FY24. The vision is to grow 30\% every year after FY24.


## 4. OTHER DEVELOPMENTS:

- Company has strong dealer network of around 1840 dealers and plans to add 150 dealers every year for the next 3 years.
- Company has spent 108 crores for brand promotion and aims to spend 135-140 crores this year.
- The capacity in Nepal was being put up with 8 MSM of two kilns which is now reduced to 1 kiln of 8 MSM and another one with 5.1 MSM that will make both ceramic and GVT. The current market size of Nepal is ~₹2,000 crore which is mostly import driven. It plans to commission the plant by March 2024.


## 5. VALUATION AND OUTLOOK:

We believe company will continue to post good results in the coming few quarters on the back of strong demand in real sector along with home improvements space. Aggressive brand promotion can reap benefits for the company in tier- 2 and tier- 3 cities.

Management is confident regarding the revenue growth of $14 \%-16 \%$ along with EBITDA margins of $14 \%-16 \%$. Aggressive revenue growth in sanitary ware and Faucet ware will drive the future growth of the company.

We give a "BUY" rating on the stock and value the stock at 42.5x of FY25E earnings to arrive at a target price of Rs. 1500 .

RECOMMENDATION - BUY CMP - 1268
TARGET - 1500 (Upside 18\%)

| Industry | Ceramics/Marble/Gran <br> ite/Sanitary ware |
| :--- | :---: |
| NSE CODE | KAJARIACER |
| BSE CODE | 500233 |
| Market Cap (₹ Cr) | 19971.71 |
| Shares Outstanding (in Cr) | 15.92 |
| 52 wk High/Low (₹) | $1325 / 915$ |
| P/E | 58.45 |
| P/BV | 8.58 |
| Face Value (₹) | 1.00 |
| Book Value (₹) | 146.11 |
| EPS (FY23) (₹) | 21.64 |
| Dividend Yield (\%) | 1.08 |
| Debt / Equity | 0.06 |
| Interest Coverage | 41.08 |

## SHAREHOLDING PATTERN

|  | Mar-23 |  | Dec-22 |  |
| :--- | :---: | :---: | :---: | :---: |
|  | Sept-22 |  |  |  |
| Promoters | 47.49 |  | 47.49 |  |
| MF/ DII | 26.23 |  | 24.49 |  |
| FII/FPI | 16.89 |  | 18.57 |  |
| Retail \& Others | 9.36 | 9.44 | 19.44 |  |
| Promoter <br> Pledging | 0.00 | 0.00 | 10.25 |  |

FINANCIAL SNAPSHOT ( $₹ \mathrm{Cr}$ )

| Y/E March | $\mathbf{2 0 2 3 A}$ | $\mathbf{2 0 2 4 E}$ | $\mathbf{2 0 2 5 E}$ |
| :--- | :---: | :---: | :---: |
| Crore |  |  |  |
| Sales | 4382 | 5040 | 5846 |
| Sales Gr. (\%) | 18.26 | 15 | 16 |
| EBITDA | 592 | 756 | 935 |
| EBITDA \% | 18.26 | 15 | 16 |
| PAT | 346 | 450 | 561 |
| EPS (₹) | 21.64 | 28.30 | 35.28 |
| EPS Gr. (\%) | -8.61 | 30.77 | 24.66 |
| BV/Sh. (₹) | 146 | 152 | 161 |
| Ratios |  |  |  |
| RoE (\%) | 15.8 | 19.33 | 23.23 |
| RoCE (\%) | 20.3 | 25 | 30 |
| Valuation |  |  |  |
| P/E (x) | 58.4 | 45.33 | 36.36 |
| P/BV (x) | 8.78 | 8.4 | 7.96 |


| Historical \& Industrial Val Ratios |  |
| :--- | :---: |
| Historical P/E | 58.45 |
| Industry P/E | 50.22 |
| Historical P/B | 8.65 |
| Industry P/B | 5.78 |

## REVENUE SPLIT (Q4FY23)



QUARTERLY PERFORMANCE (CONSOLIDATED)

| Y/E March |  |  | 22 |  |  | FY23 |  |  |  | FY24E* |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | FY23 |  |
| Net sales | 562 | 974 | 1,068 | 1,102 | 1,008 | 1,078 | 1,091 | 1,203 | 4,382 | 5040 |
| YoY change (\%) | 102.36\% | 36.64\% | 27.43\% | 15.67\% | 79.51\% | 10.70\% | 2.14\% | 9.17\% | 18.26\% | 15\% |
| Total Expenditures | 481 | 793 | 884 | 936 | 855 | 948 | 958 | 1027 | 3790 | 4284 |
| EBITDA | 80 | 180 | 184 | 166 | 154 | 129 | 133 | 176 | 592 | 756 |
| Margins (\%) | 14\% | 19\% | 17\% | 15\% | 15\% | 12\% | 12\% | 15\% | 14\% | 15\% |
| Depreciation | 27 | 28 | 28 | 33 | 32 | 34 | 33 | 34 | 133 | 156 |
| Interest | 3 | 3 | 3 | 4 | 4 | 3 | 8 | 7 | 22 | 25 |
| Other income | 6 | 7 | 7 | 7 | 8 | 4 | 7 | 6 | 26 | 25 |
| PBT | 57 | 157 | 160 | 136 | 126 | 97 | 100 | 140 | 462 | 600 |
| Rate (\%) | 27\% | 24\% | 22\% | 29\% | 26\% | 29\% | 26\% | 21\% | 25\% | 25\% |
| Adjusted PAT | 41 | 119 | 125 | 97 | 93 | 69 | 74 | 111 | 346 | 450 |
| EPS in Rs | 2.71 | 7.30 | 7.67 | 6.01 | 5.80 | 4.39 | 4.67 | 6.78 | 21.64 | 28.30 |


| Key Performance Indicators |  |  |  |  |  |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| RM cost (\% of revenue) | $34.95 \%$ | $43.37 \%$ | $42.09 \%$ | $44.20 \%$ | $37.09 \%$ | $41.93 \%$ | $40.73 \%$ | $44.6 \%$ | $41.24 \%$ | $41 \%$ |
| Employee cost (\% of revenue) | $16.61 \%$ | $10.48 \%$ | $9.98 \%$ | $9.60 \%$ | $11.35 \%$ | $10.56 \%$ | $10.68 \%$ | $9.68 \%$ | $10.53 \%$ | $11 \%$ |
| EBITDA Margins\% | $14 \%$ | $19 \%$ | $17 \%$ | $15 \%$ | $15 \%$ | $12 \%$ | $12 \%$ | $15 \%$ | $14 \%$ | $15 \%$ |
| PAT Margins \% | $7.38 \%$ | $12.26 \%$ | $11.68 \%$ | $8.83 \%$ | $9.22 \%$ | $6.39 \%$ | $6.75 \%$ | $9.2 \%$ | $7.89 \%$ | $8.92 \%$ |

Source: Company, Hem Securities Research.
*Insights into the assumptions:

- We expect revenues to grow at a rate of $15 \%$ on a YoY basis.
- Operating margins are expected to remain in line.


## INDUSTRY OVERVIEW

- India is the second largest producer of tiles in the world with market of around Rs. 42400 crores. Domestic market is expected to grow at a rate of $6 \%-8 \%$ every year.
- Export industry stands at Rs. 17500 crores and is expected to reach Rs. 20000 crores by the end of current financial year. The largest export market for India has been USA, GCC countries such as Saudi Arabia and UAE.
- Indian tile market is highly fragmented with unorganized players enjoying 60\% market share.
- Export market has witnessed a $23 \%$ CAGR over FY18-23 backed by china+1 strategy.
- $70 \%$ of the total tile production in India is done in Morbi, Gujarat.
- India exports $17 \%$ of its total production. Imports have reduced significantly and contributed only $0.1 \%$ to the overall tiles produced and consumed in India.
- Major tile players in indian markets are: Kajaria Ceramics, Somany ceramics, Johnson, Orient bell and Asian Granito.


## KEY PLAYERS



## PEER PERFORMANCE

| Particulars |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Kajaria Ceramics | Somany | Cera Sanitarywar | Asian Granito |
|  | Ltd | Ceramics Ltd | Ltd | India Ltd |
| Market Cap | 20190 | 2971 | 10107 | 1563 |
| Net Sales | 4382 | 2479 | 1804 | 1563 |
| EBITDA | 592 | 189 | 293 | -68 |
| PAT | 346 | 67 | 211 | -87 |
| EPS(₹) | 21.64 | 16.83 | 161 | -5.74 |
| EBITDA MARGIN \% | 13.5 | 7.91 | 16.2 | -4.36 |
| PAT MARGIN \% | 7.89 | 2.70 | 11.69 | - |
| ROCE \% | 20.3 | 10.4 | 25.9 | -6.58 |
| ROE \% | 15.8 | 9.03 | 19.5 | -6.69 |
| P/E TTM | 58.4 | 43 | 46.8 |  |
| P/B TTM | 8.78 | 3.73 | 8.47 | 0.49 |
| Dividend Yield \% | 0.88 | 0.45 | 0.64 | 1.50 |
| MCap/ Sales TTM | 4.66 | 1.19 | 5.51 | 0.40 |

[^0]
## STORY IN CHARTS








| ROCE and ROE |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 30.00\% | - ROCE |  | -ROE |  |  |
|  | 23.27\% | $18.78 \%$ | 22.23\% | 24.79\% | 20.30\% |
| 10.00\% | 15.72\% | 15.48\% | 17.29\% | 19.21\% | 15.80\% |
|  | - ${ }^{2}$ | $82^{20}$ | $88^{2}$ | $82^{2}$ | $8{ }^{23}$ |



## INVESTMENT RATIONALE:

- Kajaria Ceramics Ltd is a leading tiles manufacturer. They have strong distribution network. They have announced a capex of 250 crores and apart from this they are setting up a plant of 5.1 MSM in Nepal through JV.
- They have guided for a volume growth of $13 \%-15 \%$, revenue growth of $14 \%-16 \%$ along with EBITDA margins of 14-16\%.
- Easing of gas prices and softening of commodity prices augurs well for the profitability of the company.
- Positive momentum in real estate and home improvement space can reap benefits for the company.
- Management is focusing on brand building and plans to spend 135-140 crores on advertisement expenses this year. They are aiming to increase dealer network by 150 every year for the next 3 years.
- Company enjoys premium pricing as retail sales contributes $70 \%$ to the overall sales against industry average of 50\%.
- The rapid expansion in sanitaryware and Faucetware space can reap benefits for the company. They are aiming to achieve 440-450 crores of revenue sales in FY24 and aims to growth by $30 \%$ from FY24 onwards.
- They are setting up a 5.1 MSM plant in Nepal in a JV to increase their presence in the growing real estate sector in Nepal.


## RISK / NEGATIVE FACTORS:

- Economic slowdown, particularly real estate and home improvement space.
- Gas price volatility due to geopolitical tensions.
- Dip in exports due to economic recovery in China.
- Competition from unorganized players.


## COMPANY RECAP

- The company is India's largest and most respected tile manufacturer. They have 8 manufacturing facilities of tile and 2 manufacturing facilities of Bathware, located pan-India.
- Kajaria Ceramics is the largest manufacturer of ceramic/vitrified tiles in India and the 7th largest in the world. It has an annual manufacturing capacity of 81.55 MSM .
- Company currently operates 7 manufacturing plants: one at Sikandrabad (UP), one at Gailpur (Rajasthan), one at Malootana (Rajasthan), two at Morbi (Gujarat), one at Srikalahasti (Andhra Pradesh) and one at Balanagar (Telangana).
- Product verticals: 1) Ceramic Wall \& Floor Tiles, 2) Polished Vitrified tiles, 3) Glazed Vitrified Tiles, 4) Bathware (comprises of Faucets and Sanitaryware), 5) Plywood and Laminates
- Kajaria Ceramics has increased its capacity from 1 mn . sq. mtrs to 81.55 mn . sq. mtrs. in last 34 years and offers more than 3000 options in ceramic wall \& floor tiles, vitrified tiles, designer tiles and much more.
- Kajaria Ceramics exports to more than 35 countries round the Globe. The International Marketing operations are organized by a specialist export division that manages a network of international agents and distributors.
- They are the only Indian Tile company to receive the revered "Asia's Most Promising Brand" award in the Premium Tiles category.
- They have a strong brand presence, they are associated with Bollywood actor Akshay Kumar for Kajaria Tiles and Ranveer Singh for Kajaria Ply.
- Key Management personnel - Mr. Ashok Kajaria ( Chairman and Managing Director), Mr. Chetan Kajaria (Joint Managing Director), Mr. Rishi kajaria (Joint Managing Director)


## ANNUAL PERFORMANCE

Financials \& Valuations

| Income Statement |  |  |  |  |  | F Fr |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Y/E March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E |
| Revenue from operations | 2,956.20 | 2,808.01 | 2,780.90 | 3,705.19 | 4,382 | 5,040 | 5846 |
| Growth YoY (\%) | 9.06 | -5.01 | -0.97 | 33.24 | 18.26 | 15 | 16 |
| Total Expenditure | 2,506.71 | 2,392.11 | 2,272.08 | 3,094.50 | 3,790 | 4284 | 4910 |
| (\%) of sales | 84.80 | 85.19 | 81.70 | 83.52 | 86 | 85 | 84 |
| EBITDA | 449.49 | 415.90 | 508.82 | 610.69 | 592 | 756 | 936 |
| EBITDA Growth (\%) | 0.07 | -5.88 | 20.47 | 20.40 | -3.26 | 27.70 | 23.80 |
| EBITDA Margin (\%) | 15.81 | 15.67 | 18.26 | 16.52 | 14 | 15 | 16 |
| Depreciation | 89.06 | 108.09 | 106.67 | 115.36 | 133 | 156 | 181 |
| EBIT | 373.62 | 331.96 | 423.45 | 522.90 | 459 | 600 | 755 |
| EBIT Growth (\%) | -1.53 | -11.15 | 27.56 | 23.49 | 12.23 | 30.71 | 25.83 |
| Net Interest Expenses | 15.59 | 19.51 | 10.71 | 12.73 | 22 | 25 | 30 |
| Other Income | 18.03 | 24.15 | 21.30 | 27.57 | 26 | 25 | 23 |
| Earnings before Taxes | 358.03 | 312.45 | 412.74 | 510.17 | 462 | 600 | 748 |
| EBT Margin (\%) | 12.11 | 11.13 | 14.21 | 13.20 | 10.54 | 11.90 | 12.79 |
| Tax-Total | 129.28 | 58.92 | 103.84 | 127.43 | 116 | 150 | 187 |
| Rate of tax (\%) | 36.11 | 18.86 | 25.16 | 24.98 | 25 | 25 | 25 |
| Net Profit | 228.75 | 253.53 | 308.90 | 382.74 | 346 | 450 | 561 |
| PAT Growth (\%) | 0.07 | 10.83 | 21.84 | 23.90 | -9.66 | 30.05 | 24.66 |
| PAT Margin (\%) | 7.74 | 9.03 | 10.64 | 9.91 | 7.89 | 8.92 | 9.56 |
| EPS | 14.25 | 16.06 | 19.36 | 23.68 | 21.64 | 28.30 | 35.28 |
| EPS Growth (\%) | -3.57 | 12.69 | 20.57 | 22.30 | -8.61 | 30.77 | 24.66 |


| Balance Sheet | $\mathbf{2 0 1 9}$ | $\mathbf{2 0 2 0}$ | $\mathbf{2 0 2 1}$ | $\mathbf{2 0 2 2}$ | $\mathbf{2 0 2 3}$ |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Y/E March | 16 | 16 | 16 | 16 | 16 |
| Share Capital | 1,559 | 1,698 | $\mathbf{1 , 8 5 3}$ | $\mathbf{2 , 1 0 6}$ | $\mathbf{2 , 3 1 1}$ |
| Reserves | $\mathbf{1 5 7 5}$ | $\mathbf{1 7 1 4}$ | $\mathbf{1 8 6 9}$ | $\mathbf{2 1 2 2}$ | $\mathbf{2 3 2 7}$ |
| Net Worth | 120 | 166 | 126 | 165 | $\mathbf{2 5 0}$ |
| Borrowings | 677 | 557 | 530 | 699 | $\mathbf{7 5 4}$ |
| Other Liabilities | $\mathbf{2 , 3 7 2}$ | $\mathbf{2 , 4 3 7}$ | $\mathbf{2 , 5 2 5}$ | $\mathbf{2 , 9 8 6 7}$ | $\mathbf{3 , 3 3 1}$ |
| Total Liabilities \& Equity | $\mathbf{1 , 0 7 8}$ | $\mathbf{1 , 1 9 5}$ | $\mathbf{1 , 1 9 2}$ | $\mathbf{1 , 1 5 0}$ | $\mathbf{1 , 4 4 7}$ |
| Fixed Assets | 93 | 27 | 15 | $\mathbf{2 6 3}$ | $\mathbf{8 2}$ |
| CWIP | 0 | 10 | 5 | 0 | $\mathbf{2}$ |
| Investments | 1,200 | $\mathbf{1 , 2 0 6}$ | $\mathbf{1 , 3 1 3}$ | $\mathbf{1 , 5 7 3}$ | $\mathbf{1 8 0 0}$ |
| Other Assets | $\mathbf{2 , 3 7 2}$ | $\mathbf{2 , 4 3 7}$ | $\mathbf{2 , 5 2 5}$ | $\mathbf{2 , 9 8 6}$ | $\mathbf{3 , 3 3 1}$ |
| Total Assets |  |  |  |  |  |

[^1]| Ratios |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Y/E March (Basic (INR) | 2019 | 2020 | 2021 | 2022 | 2023 |
| Profitability and return ratios |  |  |  |  |  |
| Net profit margin (\%) | 7.74 | 9.03 | 10.64 | 9.91 | 7.89 |
| EBITDA margin (\%) | 15.81 | 15.67 | 18.26 | 16.52 | 14 |
| EBIT margin (\%) | 12.64 | 11.82 | 14.58 | 13.53 | 11.06 |
| ROE (\%) | 15.72 | 15.48 | 17.29 | 19.21 | 15.8 |
| ROCE (\%) | 23.27 | 18.78 | 22.23 | 24.79 | 20.3 |
| Working Capital \& liquidity ratios |  |  |  |  |  |
| Payables (Days) | 112 | 88 | 66 | 78 | 63 |
| Inventory (Days) | 147 | 189 | 119 | 122 | 114 |
| Receivables (Days) | 59 | 52 | 57 | 51 | 50 |
| Current Ratio (x) | 2.00 | 2.30 | 2.81 | 2.20 | 2.27 |
| Valuations Ratios 2.2 .80 |  |  |  |  |  |
| EV/sales ( x ) | 3.13 | 2.10 | 5.16 | 4.29 | 4.57 |
| EV/EBITDA (x) | 19.81 | 13.39 | 27.09 | 24.92 | 32 |
| P/E (x) | 41.45 | 23.45 | 47.73 | 42.99 | 57.6 |
| P/BV (x) | 5.99 | 3.50 | 7.88 | 7.64 | 8.68 |
| Dividend Yield (\%) | 0.51 | 0.80 | 1.08 | 1.08 | 0.87 |
| Leverage Ratio |  |  |  |  |  |
| Debt/Equity (x) | 0.08 | 0.07 | 0.05 | 0.06 | 0.11 |


| Cash Flow Statement |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Y/E March | $\mathbf{2 0 1 9}$ | $\mathbf{2 0 2 0}$ | $\mathbf{2 0 2 1}$ | $\mathbf{2 0 2 2}$ | $\mathbf{2 0 2 3}$ |
| CF from Operating activities (A) | 317 | 224 | 509 | 426 | $\mathbf{2 9 6}$ |
| CF from Investing Activities (B) | -261 | -90 | -296 | -297.91 | -184 |
| CF from Financing Activities (C) | -114 | -140 | -205 | -120 | -135 |
| Net Cash Flow | -57.64 | -6 | 8.71 | 7 | -23 |
| Add: Opening Bal. | 80 | 22 | 16 | 25 | 32 |
| Closing Balance | 22 | 16 | 25 | 32 | 9 |

[^2]
## RATING CRITERIA

| INVESTMENT RATING | EXPECTED RETURN |
| :--- | :--- |
| BUY | $>=15 \%$ |
| ACCUMULATE | $5 \%$ to $15 \%$ |
| HOLD | 0 to $5 \%$ |
| REDUCE | $-5 \%$ to 0 |
| SELL | $<-5 \%$ |

## RECOMMENDATION SUMMARY

| DATE | RATING | TARGET |
| :--- | :--- | :--- |
| $29^{\text {th }}$ June 2023 | Buy | 1500 |

$\qquad$
$\square$
$\square$

## DISCLAIMER

HEM Securities Limited ("Research Entity or HSL") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and other related activities. Broking services offered by HEM Securities Limited are under SEBI Registration No.: INZ000168034.

This Report has been prepared by HEM Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH100002250 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. This should not be construed as invitation or solicitation to do business with HSL. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject HSL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. HSL reserves the right to make modifications and alterations to thisstatement as may be required from time to time. HSL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. HSL is committed to providing independent and transparent recommendation to its clients. Neither HSL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance
.The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

HSL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.

## ANALYST CERTIFICATION/ DISCLOSURE OF INTEREST

Name of the Research Analyst: MUDIT JAIN
The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

| SN | Particulars | Yes/No |
| :---: | :---: | :---: |
| 1. | Research Analyst or his/her relative's or HSL's financial interest in the subject company(ies) | No |
| 2. | Research Analyst or his/her relative or HSL's actual/beneficial ownership of $1 \%$ or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the Research Report | No |
| 3. | Research Analyst or his/her relative or HSL has any other material conflict of interest at the time of publication of the Research Report | No |
| 4. | Research Analyst has served as an officer, director or employee of the subject company(ies) | No |
| 5. | HSL has received any compensation from the subject company in the past twelve months | No |
| 6. | HSL has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months | No |
| 7. | HSL has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months | No |
| 8. | HSL has received any compensation or other benefits from the subject company or third party in connection with the research report | No |
| 9. | HSL has managed or co-managed public offering of securities for the subject company in the past twelve months | No |
| 10. | Research Analyst or HSL has been engaged in market making activity for the subject company(ies) | No |

Since HSL and its associates are engaged in various businesses in the financial services industry, they may have financial interest or may have received compensation for investment banking or merchant banking or brokerage services or for any other product or services of whatsoever nature from the subject company(ies) in the past twelve months. Associates of HSL may have actual/beneficial ownership of $1 \%$ or more and/or other material conflict of interest in the securities discussed herein.

There were no instances of non-compliance by HSL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years.


[^0]:    Source: Company, Hem Securities Research.

[^1]:    Source: Company, Hem Securities Research.

[^2]:    Source: Company, Hem Securities Research.

